US OptionsDetailed Quotes
JAZZ240719C95000
- 12.70
- 0.000.00%
15min DelayClose Jul 19 16:00 ET
0.00High0.00Low
12.70Open12.70Pre Close0 Volume10 Open Interest95.00Strike Price0.00Turnover0.00%IV-1.20%PremiumJul 19, 2024Expiry Date14.01Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.81Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Jazz Pharmaceuticals Stock Discussion
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
$Iovance Biotherapeutics(IOVA.US$ Phase 2
$Supernus Pharmaceuticals(SUPN.US$ Phase 2a
$BRANDES INTERNATIONAL ETF(BINV.US$ Phase 2a
$MorphoSys(MOR.US$ Phase 2
$Nuvation Bio(NUVB.US$ Phase 2
$ALX Oncology(ALXO.US$ Phase 2
$BioXcel Therapeutics(BTAI.US$ Phase 2
$Purple Biotech(PPBT.US$ Phase 2
$Arcus Biosciences(RCUS.US$ Phase 2
$Medicenna Therapeutics(MDNAF.US$ Phase 2b
$Affimed NV(AFMD.US$ Phase 2
$Barinthus Biotherapeutics(BRNS.US$ Phase 2b...
13
3
$Esperion Therapeutics(ESPR.US$ Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
3
Despite Jazz Pharmaceuticals' revenue growth and profitability, its share price drop may signal unresolved issues. The long-term share price weakness could be a bad sign, yet contrarian investors might see a potential turnaround opportunity.
1
The low ROE and high debt usage of Jazz Pharmaceuticals make it a less exciting investment at the moment. The company's performance could be impacted if it was unable to borrow as easily in changing credit markets.
Jazz Pharmaceuticals' low P/S ratio is due to slower revenue growth compared to industry trend, leading to discomfort amongst shareholders and stock devaluation. Persisting sluggish growth may decrease P/S ratio even further unless fortunes change.
Analyst Joon Lee supports the potential split of Jazz's businesses given its growing oncology unit and competitive CNS franchise, valuing Jazz at $200 per share. Alternatively, Jason Gerberry suggests selling the oncology unit and focusing on CNS or spin-off maybe more likely than a total sale, with a 'buy' rating and $217 price target remaining.
follow for daily best watch ⭐️
Keep a watch on FTNT and AYX
$Activision Blizzard(ATVI.US$ $Biodexa Pharmaceuticals(BDRX.US$ $Cadrenal Therapeutics(CVKD.US$ $Eastside Distilling(EAST.US$ $Eloxx Pharmaceuticals(ELOX.US$ $Freeline Therapeutics(FRLN.US$ $Fortinet(FTNT.US$ $Illumina(ILMN.US$ $Jazz Pharmaceuticals(JAZZ.US$ $MetLife(MET.US$ $NanoString Technologies(NSTG.US$ $PainReform(PRFX.US$ $Prestige Wealth(PWM.US$ $Sientra(SIEN.US$ $Vmware(VMW.US$
Keep a watch on FTNT and AYX
$Activision Blizzard(ATVI.US$ $Biodexa Pharmaceuticals(BDRX.US$ $Cadrenal Therapeutics(CVKD.US$ $Eastside Distilling(EAST.US$ $Eloxx Pharmaceuticals(ELOX.US$ $Freeline Therapeutics(FRLN.US$ $Fortinet(FTNT.US$ $Illumina(ILMN.US$ $Jazz Pharmaceuticals(JAZZ.US$ $MetLife(MET.US$ $NanoString Technologies(NSTG.US$ $PainReform(PRFX.US$ $Prestige Wealth(PWM.US$ $Sientra(SIEN.US$ $Vmware(VMW.US$
2
Seth Klarman’s 13F portfolio value decreased from $6.13B to $5.85B this quarter.
Baupost Group increased Alphabet and Fidelity National Information Services while dropping Meta Platforms, Micron Technology, and Amazon.com.
The portfolio continues to be heavily concentrated with the top three positions accounting for ~40% of the 13F portfolio.
New Stakes:
$Skyworks Solutions(SWKS.US$ and $Jazz Pharmaceuticals(JAZZ.US$
Stake Disposals:
$Meta Platforms(META.US$
...
Baupost Group increased Alphabet and Fidelity National Information Services while dropping Meta Platforms, Micron Technology, and Amazon.com.
The portfolio continues to be heavily concentrated with the top three positions accounting for ~40% of the 13F portfolio.
New Stakes:
$Skyworks Solutions(SWKS.US$ and $Jazz Pharmaceuticals(JAZZ.US$
Stake Disposals:
$Meta Platforms(META.US$
...
7
No comment yet
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long